
    
      During the acute dysphagia evaluation phase (the period lasting from the administration of
      the first dose of investigational product through Week 12 (or up to Week 16 if dysphagia is
      not resolved to CTCAE v3.0 grade â‰¤ 1 by Week 12) participants underwent acute dysphagia
      assessments twice weekly. All participants were followed for disease progression, second
      primary tumors, other malignancies, and overall survival until death or loss to follow-up
      during the long term follow-up (still ongoing).
    
  